H.P. Acthar Gel is a highly purified preparation of adrenocorticotropic hormone (ACTH) in a gel that is designed to provide extended release of the ACTH following injection. ACTH stimulates the adrenal cortex gland to secrete cortisol, corticosterone, and aldosterone.
ACTH was approved in 1978 by the U.S. Food and Drug Administration (FDA) as a short-term treatment for acute exacerbations of MS. According to its FDA labeling, corticosteroids (such as methylprednisolone or dexamethasone) are considered the treatment of choice for acute exacerbations. ACTH is available for those individuals who cannot tolerate the side effects of high dose corticosteroids; have been treated unsuccessfully with corticosteroids in the past; prefer the convenience of self-injection; or have difficulty receiving intravenous medication because of poor venous access. ACTH is included in the updated list of medications covered under the Medicare Replacement Drug Demonstration Project.
Click here to read the H.P. Acthar Gel Prescribing Information for healthcare professionals.
Click here to read the H.P. Acthar Gel Medication Guide for patients.
Acthar Support and Access Program (A.S.A.P.) Phone:1-888-435-2284 Fax: 1-877-937-7274
Financial Assistance Program
Acthar Support & Access Program (A.S.A.P.) 1-888-435-2284